Paloma-2 trial
WebApr 19, 2016 · PALOMA-2 is a randomized (2:1), multicenter, multinational, double-blind Phase 3 study designed to assess PFS in postmenopausal women with ER+, HER2- … WebFinn RS, Martin M, Rugo HS, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal …
Paloma-2 trial
Did you know?
WebJun 19, 2024 · The clinical patterns of neutropenia and other hematologic toxicities with palbociclib were consistent with observations in PALOMA-1 and PALOMA-3 13, 14, 16 and rarely led to permanent treatment discontinuation in PALOMA-2; although neutropenia occurred at a higher frequency than other AEs, the incidence of febrile neutropenia … WebMay 30, 2024 · PALOMA-1 was an open-label phase II trial comparing progression-free survival (PFS) in patients (pts) with advanced ER+/HER2– BC treated with P+L or L alone. Median PFS increased with addition of P to L to 20.2 mos (vs 10.2 mos with L alone; HR = 0.488), with an acceptable safety profile, leading to accelerated approval by the US FDA.
WebThe designs of the MONALEESA-2 and PALOMA-2/PALOMA-1 trials were similar and were, therefore, considered suitable for comparison. Of the MONALEESA-2 ITT population, 334 patients were treated with RIBO and LET and 334 patients were treated with placebo and LET. In the PALOMA-2 trial, 444 patients were treated with PALBO and LET and … WebJun 10, 2024 · The phase III PALOMA-2 study, conducted by Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and …
WebJun 4, 2024 · The PALOMA-2 trial showed that in addition to substantially delaying progressive disease, IBRANCE as first-line treatment, in combination with letrozole, delayed time to chemotherapy (38.1 months vs 29.8 months; HR, 0.73), while maintaining quality of life with no new identified safety issues.
WebAug 16, 2024 · A total of 455 and 302 tumors from PALOMA-2 and PALOMA-3 trials, respectively, were successfully collected and analyzed for gene expression using the …
WebOther trials also investigating CDK4/6 inhibitors as first-line therapy in postmenopausal patients (PALOMA-2 and MONARCH 3) have yet to report final overall survival. funny wedding vow renewal ceremonyWebDec 12, 2024 · In the pivotal, double-blind phase III PALOMA-2 study, postmenopausal women with ER-positive/HER2-negative advanced breast cancer were randomized in a 2:1 ratio to frontline treatment with... funny wedding vows about footballWebRecently, the PALOMA-3 trial assessed overall survival with either palbociclib or placebo plus fulvestrant in patients with hormone-receptor–positive, HER2-negative advanced breast cancer;... funny wedding vow renewalsWebPurpose: In the initial PALOMA-2 ( NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) … githacker-masterWebJan 19, 2024 · Patient-reported health-related QOL (HRQOL) outcomes, a secondary objective in the PALOMA-2 trial, were assessed using the fully validated Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQOL 5 dimensions (EQ-5D) questionnaires at baseline, day 1 of cycles 2 and 3, and day 1 of every alternate cycle … gith 5e artWebIn the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC. githacker 429WebAbstract Background: PALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). githack ctfhub